Insomnia therapeutic - Blake Insomnia Therapeutics

Drug Profile

Insomnia therapeutic - Blake Insomnia Therapeutics

Alternative Names: Zleepax; ZLX-1

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zleepax
  • Developer Blake Insomnia Therapeutics
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Insomnia

Most Recent Events

  • 28 Aug 2017 Blake Insomnia Therapeutics files a clinical trial application with the Health Canada for Insomnia
  • 28 Aug 2017 Blake Insomnia Therapeutics plans a phase IIb trial for Insomnia
  • 02 Mar 2017 Blake Insomnia Therapeutics and Sajo Consulting plan clinical trials for Insomnia in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top